The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | J | Antiinfectives for systemic use | |
| 2 | J06 | Immune sera and immunoglobulins | |
| 3 | J06B | Immunoglobulins | |
| 4 | J06BD | Antiviral monoclonal antibodies | |
| 5 | J06BD08 |
| Active Ingredient | Description | |
|---|---|---|
| Nirsevimab |
Nirsevimab is a recombinant neutralising human IgG1ĸ long-acting monoclonal antibody to the prefusion conformation of the RSV F protein which has been modified with a triple amino acid substitution (YTE) in the Fc region to extend serum half-life. Nirsevimab inhibits the essential membrane fusion step in the viral entry process, neutralising the virus and blocking cell-to-cell fusion. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| BEYFORTUS Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
